| Title: |
Interferon-β can induce progesterone receptors in human endometrial adenocarcinoma |
| Authors: |
Codegoni A. M.; Landoni F.; Lomonico S.; Losa G.; Mangioni C.; Taverna M.; Lucchini V.; D'Incalci M. |
| Contributors: |
Codegoni, A; Landoni, F; Lomonico, S; Losa, G; Mangioni, C; Taverna, M; Lucchini, V; D'Incalci, M |
| Publisher Information: |
WILEY |
| Publication Year: |
1996 |
| Collection: |
Università degli Studi di Milano-Bicocca: BOA (Bicocca Open Archive) |
| Subject Terms: |
endometrial adenocarcinoma; estrogen receptor; hIFN-β; progesterone receptor; Adenocarcinoma; Adult; Aged; 80 and over; Endometrial Neoplasm; Female; Human; Interferon-beta; Middle Aged; Receptors; Estrogen; Progesterone |
| Description: |
BACKGROUND. The induction of estrogen and progesterone receptors (ER and PGR) has been reported in breast and endometrial cancer cells exposed to human fibroblast interferon-β (hlFN-β). Clinical verification of this finding might provide the rationale for new therapeutic approaches. This study was designed to evaluate whether clinical treatment with high doses of hlFN-β induced ER and PGR in patients with endometrial adenocarcinoma. METHODS. Two biopsies were obtained, 1 before and 1 after hlFN-β treatment (3 x 106 i.m. every other day for 3 weeks) from 36 patients with endometrial adenocarcinoma. ER and PGR were determined with standard procedures using radiolabeled ligands. RESULTS. hIFN-β treatment did not affect the proportion of ER-positive (i.e., > 15 fmol/mg protein) or PGR-positive (i.e., >20 fmol/mg protein) cases. However, in patients with detectable ER and PGR at baseline, hIFN-β raised the levels. Using a 35% difference before and after therapy as a cut-off, 72 and 79% of cases had increases in ER and PGR, respectively. The difference was highly significant for PGR. CONCLUSiONS. In patients with endometrial adenocarcinoma with undetectable ER or PGR, hIFN- β did not induce the expression of these receptors. When the receptors were present they were upregulated by hIFN-β. Whether this increase in receptor levels, particularly PGR, has therapeutic applications remains to be established |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/8697390; info:eu-repo/semantics/altIdentifier/wos/WOS:A1996UY25400011; volume:78; issue:3; firstpage:448; lastpage:453; numberofpages:6; journal:CANCER; https://hdl.handle.net/10281/265081 |
| Availability: |
https://hdl.handle.net/10281/265081 |
| Accession Number: |
edsbas.2528CF8 |
| Database: |
BASE |